Inve India ▾

Shalby share price & results

Shalby Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

India's largest joint-replacement hospital chain, also manufacturing orthopedic implants for global markets.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue331 ₹ crore+11.8% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin13.0 %−1.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit10.0 ₹ crore+25.0% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity3.78 %+3.7 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin-12.71 %−5.9 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)6.33 %−11.4 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

2 of 6 judged targets kept · 12 open · verdicts reflect calls analysed to Q1 FY27.

Shalby Limited management guidance track record on Inve: 18 targets tracked across analysed earnings calls (2 achieved, 4 missed, 12 open).

TargetOriginal wordingSaidLatest callVerdict
Effective Tax RateFY26 tax rate will be somewhere around 25%
Call transcript, Q4 FY25 · 31 May 2025		Q4 FY25Q1 FY27:Confirmed transition to lower tax rate of ~26% for hospital segment.
Call transcript, Q1 FY27 · 13 Aug 2026		Achieved
Consolidated Revenue GrowthHigher single-digit growth for FY26
Call transcript, Q4 FY25 · 31 May 2025		Q4 FY25Q1 FY27:FY26 target, no new update.
Call transcript, Q1 FY27 · 13 Aug 2026		Missed
Hospital and Pharma Business Revenue CAGRminimum 15% CAGR
Call transcript, Q4 FY26 · 29 May 2026		Q4 FY26Q1 FY27:Hospital segment revenue grew 7% YoY, below the 15% target.
Call transcript, Q1 FY27 · 13 Aug 2026		At Risk

Source: Inve Guidance Tracker for Shalby Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

4 of Shalby Limited's 18 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 15 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹118.68 +2.94% · +₹3.39

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance −51.6% 1Y

₹150₹200₹250Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 14 Nov 2025Q3 FY26 — 12 Feb 2026Q4 FY26 — 29 May 2026Q1 FY27 — 13 Aug 2026

1Y: ₹245.4 on 24 Oct 2025 → ₹118.68. High ₹245.4 (24 Oct 2025), low ₹113.39 (23 Oct 2026).

Previous close
₹115.29
Market cap
₹1.2k Cr
52-week range
₹113.39 – ₹245.35
One year
−50.87%
Price to earnings (TTM to Jun 2026)
32.93×
Return on equity (TTM to Jun 2026)
3.78%

Overview

Symbol
NSE:SHALBY
Exchange
NSE
Currency
INR

What Shalby Limited does

Based on the company's own presentations, annual report and earnings calls.

Shalby Limited runs a network of multi-specialty hospitals across India built on the joint-replacement surgery practice pioneered by founder Dr. Vikram Shah, and has since diversified into cardiac science, oncology, neuroscience, critical care, general medicine and organ transplants. It earns from in-patient and out-patient hospital care delivered through owned, franchised and O&M (operate-and-maintain) facilities, plus hospital operations outside its core network including PK Healthcare in Delhi-NCR. A separate MedTech vertical designs, manufactures and distributes orthopedic implants through its Shalby MedTech subsidiary, which includes a US manufacturing arm (Shalby Advanced Technologies) and a Singapore-based distribution arm (Shalby Global Technologies).

Segments

  • Shalby Hospitals, Pharma & Franchise
  • Shalby International
  • Shalby MedTech
Hospitals (across 10 cities in India)
13
Total bed capacity
2,200+
Domestic outpatient (OPD) clinics
60
International OPD clinics
23
Doctors team (incl. visiting consultants)
1,150+
Total employees
4,500+
Founded 1994Headquarters Ahmedabad, Gujarat, India Company website

How the price took the results

close before → close after

Q1 FY27
−0.7%
13 Aug
Q4 FY26
−2.0%
29 May
Q3 FY26
−6.2%
12 Feb
Q2 FY26
−0.7%
15 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Shalby Limited

Free account: one company. Everything above stays public.

Write why you follow Shalby Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Shalby Limited

Guides on how to read this kind of business and the numbers that matter.